GBA1 and Gaucher disease type II: For instance, AAV-GBA1, designed to address GBA1 mutations in type II Gaucher disease, can also be repurposed to target Parkinson’s disease, given that GBA-1 mutations represent a common genetic risk factor for both conditions.148